Insights into pparγphosphorylation and its inhibition mechanism
PPARγrepresents a key target for the treatment of type 2 diabetes and metabolic syndrome. Synthetic antidiabetic drugs activating PPARγare accompanied by serious undesirable side effects related to their agonism. In the search for new PPARγregulators, inhibitors of PPARγphosphorylation on S245 mediated by CDK5 represent an opportunity for the development of an improved generation of antidiabetic drugs acting through this nuclear receptor.